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Contrast-induced acute kidney injury (CI-AKI), also known
as contrast-induced nephropathy, is a common complication
of intra-arterial administration of iodinated radiographic
contrast medium (IRCM) that may prolong the duration of
hospitalization and increase the risk of death (1,2). CI-AKI
is characterized by an increase in serum creatinine beginning
within the ﬁrst 24 h of IRCM exposure and peaking at up to
5 days after exposure. CI-AKI is deﬁned most commonly as
a rise in serum creatinine concentration 0.5 mg/dl or 25%
above baseline assessed 48 to 72 h after exposure to contrast
(1,2). More recently, the Acute Kidney Injury Network
deﬁned CI-AKI as a rise in serum creatinine of 0.3 mg/dl
above baseline with oliguria (1).
See pages 62 and 71
Patients with chronic kidney disease (CKD) are
vulnerable to CI-AKI, particularly in the presence of risk
factors such as diabetes mellitus and clinical states associ-
ated with decreased renal perfusion (1,2). McCullough
(1) proposed a pathophysiologic sequence for CI-AKI.
He postulated that entry of IRCM into the renal vascula-
ture initially produces endothelium-independent transient
vasodilation, followed by adenosine release from the macula
densa, endothelin release, and prostaglandin dysregulation
(causing decreased nitric oxide synthesis and release).
Sustained intrarenal vasoconstriction subsequently occurs
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medullary hypoxia (1). These sequelae are thought to
predispose to direct cellular injury and apoptotic death,
ischemic cellular injury and cell death, increased oxidative
stress and inﬂammation, ultimately resulting in CI-AKI
(1,2). Many of the therapeutic interventions studied to
determine their efﬁcacy in reducing the risk of CI-AKI
directly or indirectly affect various elements of this path-
ophysiologic cascade (1,2). Therapies proven to reduce
the risk of CI-AKI include periprocedural intravenous
hydration and use of low volumes of low osmolality, or iso-
osmolar, nonionic IRCM (1,2). Use of pre-procedural
N-acetylcysteine has produced mixed results (1,2).
Therapy with theophylline, iloprost, trimetazidine, endo-
vascular cooling, targeted renal therapy with fenoldapam,
and removal of IRCM from the coronary sinus have shown
promise but require further study (1,2). Conversely,
ascorbic acid, various diuretics, dipyridamole, and non-
selective antagonism of endothelin receptors have shown
no beneﬁt or worsening of renal function following
administration of IRCM (1,2).
In recent years there has been increasing interest in the
role of 3-hydroxy-3-methylglutaryl coenzyme A reductase
inhibitors (statins) in reducing the risk of CI-AKI in
patients undergoing coronary angiography (CA) and/or
percutaneous coronary interventions (PCI) (3–11). This is
due primarily to their anti-inﬂammatory properties and their
abilities to improve endothelial function, but also because of
their antiapoptotic effects, which have been demonstrated in
pre-clinical and clinical studies (3–11). Since 2005, 5 cohort
studies, only 1 of which was prospective, showed a signiﬁ-
cantly lower incidence of CI-AKI in patients receiving long-
term statin therapy than in those not receiving a statin (3–5).
Since 2008, 9 randomized clinical trials (RCTs) have
prospectively assessed the effects of short-term administra-
tion of statins pre- and post-procedure on the development
of CI-AKI in patients undergoing CA and/or PCI. Three
of these RCTs showed a signiﬁcantly lower incidence of CI-
AKI in patients receiving intermediate-to-high dose statin
therapy pre-procedure than in those who did not receive
a statin (3–11). Three studies showed a signiﬁcantly lower
incidence of CI-AKI in patients receiving intermediate-to-
high dose statin therapy pre-procedure than in those
receiving low-dose statin therapy (3–11). In 3 other RCTs,
statin therapy had no effect on the incidence of CI-AKI.
Results of meta-analyses of these trials tend to support the
use of statins to reduce the risk of CI-AKI in this patient
population (3–11). However, given the substantial hetero-
geneity among trials and the fact that several studies re-
ported no reduction in the risk of CI-AKI, the authors of
these meta-analyses acknowledged the need for additional
RCTs to clarify this issue.
Two studies reported in this issue of the Journal provide
new insights into the role of statins in reducing the risk of
renal injury in patients at high risk for CI-AKI (12,13).
Both studies are well designed prospective RCTs and are the
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the development of CI-AKI.
In the study by Leoncini et al. (12), 504 statin-naive
patients with non-ST segment acute coronary syndromes
(NST-ACS) were studied to assess the effect of high-dose
pre-procedure rosuvastatin on the development of CI-
AKI. All patients were selected to undergo an early invasive
strategy and underwent CA alone or CA with PCI. One
group received rosuvastatin, 40 mg, on admission, followed
by 10 to 20 mg of rosuvastatin daily (depending on renal
function) until discharge. The other group received no statin
therapy during hospitalization. Both groups received rosu-
vastatin after discharge. The incidence of CI-AKI was 6.7%
in patients receiving rosuvastatin during their hospitalization
compared to 15.1% in those not treated with a statin during
their hospitalization (p ¼ 0.003). The absolute reduction in
CI-AKI risk in rosuvastatin-treated patients was 8.3%, and
the number needed to treat to prevent CI-AKI was 12. The
results were consistent using multiple alternative deﬁnitions
of CI-AKI and after adjusting for age, sex, creatinine
clearance, left ventricular ejection fraction, and Mehran risk
score. The 30-day composite endpoint of death, dialysis,
myocardial infarction (MI), stroke, or persistent renal
damage occurred in 3.6% of patients receiving rosuvastatin
and in 7.9% of those who did not receive rosuvastatin during
hospitalization. At 6 months, the incidence of death or
nonfatal MI was 3.6% in patients who received periproce-
dural rosuvastatin and 7.9% in those who did not receive
a statin while hospitalized (p ¼ 0.07).
Han et al. (13) studied 2,998 patients with type 2 diabetes
mellitus and stage 2 or 3 CKD, scheduled to undergo CA,
PCI, peripheral arterial angiography, or peripheral arterial
intervention to determine the effects of periprocedural
rosuvastatin therapy on the development of CI-AKI. Of the
2,998 patients, 84.5% underwent cardiac procedures and
>70% presented with NST-ACS. All patients were either
statin naive or had not received a statin for at least 2 weeks
prior to entry. One group was randomized to receive rosu-
vastatin, 10 mg daily, for 2 days prior to their procedure and
daily for 3 days thereafter. The other group received no
statin during this 5-day period. Both of the groups received
statin therapy after 5 days. CI-AKI occurred in 2.3% of
patients receiving periprocedural rosuvastatin and 3.9% of
patients who did not receive periprocedural statin therapy
(p ¼ 0.01). The beneﬁcial effect on CI-AKI occurred
exclusively in patients with stage-2 CKD (1.5% vs. 3.3%,
respectively; p ¼ 0.01; number needed to treat ¼ 62).
Independent predictors of CI-AKI were rosuvastatin
therapy, NST-ACS, New York Heart Association func-
tional class, blood hemoglobin, and estimated glomerular
ﬁltration rate <60 ml/min/1.73 m2. High-sensitivity C-
reactive protein levels were signiﬁcantly higher in patients
who developed CI-AKI than in those who did not. At 30
days, worsening heart failure was present in 2.6% of patients
who had received periprocedural rosuvastatin and in 4.3% of
those who did not (p ¼ 0.02), whereas the incidence ofall-cause deaths or dialysis/hemoﬁltration was similar
between the two groups.
As previously noted, the studies by Leoncini et al. (12)
and Han et al. (13) are the ﬁrst large-scale studies assess-
ing the effect of rosuvastatin on CI-AKI risk. Rosuvastatin is
a hydrophilic statin with potent anti-inﬂammatory properties
independent of its cholesterol-lowering effect (14). Like other
statins, it improves endothelial function, probably by
increasing nitric oxide synthetase bioavailability, and
decreases oxidative stress (14). All of these properties
counteract speciﬁc pathophysiologic mechanisms that
promote the development of CI-AKI. Whether these
properties of rosuvastatin were responsible for the beneﬁts
noted in these studies is uncertain. Moreover, there are no
large head-to-head studies involving rosuvastatin to deter-
mine whether it is superior to other statins in reducing the
risk of CI-AKI and its intermediate and long-term sequelae.
Both of these studies focused on patients who were at
high risk for CI-AKI, speciﬁcally those with NST-ACS and
diabetics with varying degrees of CKD (12,13). Both
selected patients who were statin naive or those who had not
recently received statin therapy (12,13).
The study by Leoncini et al. (12) suggested that rosu-
vastatin was most effective in reducing the risk of CI-AKI in
patients with mild to moderate renal dysfunction (12),
whereas the results of the study by Han et al. (13) showed
that only patients with stage 2 CKD beneﬁted from rosu-
vastatin therapy. Leoncini et al. (12) emphasized the
importance of administration of high-dose statin therapy
prior to exposure to IRCM, as have other studies assessing
the effects of short-term statin therapy on CI-AKI (3–12).
However, the dose of rosuvastatin used in the study by Han
and colleagues (13) was low (10 mg), yet the incidence of
CI-AKI was also signiﬁcantly lower than in those who did
not receive periprocedural statin therapy. Although >70%
of patients in the study by Han et al. (13) presented with
NST-ACS, the incidence of CI-AKI was substantially lower
in both statin-treated and non-statin-treated groups than in
the study by Leoncini et al. (12). This may be due to
differences in patient composition between the two studies.
Both of the studies underscored the fact that risk of adverse
renal and cardiovascular outcomes does not end at 5 days in
patients with CI-AKI (12,13).
Results of these studies support the use of short-term
periprocedural statin therapy to reduce the risk of CI-AKI
and its intermediate to long-term sequelae in patients at
high risk for this disorder who undergo CA or PCI (12,13).
Future studies should attempt to focus on relatively homo-
geneous patient populations or those large enough to
support pre-speciﬁed subset analysis. Such studies should
attempt to determine which stages of CKD are beneﬁted
most by periprocedural statin therapy. Head-to-head
comparison of commercially available hydrophilic and lipo-
philic statins at both high and low doses would help to
determine whether differences exist in their abilities to
reduce CI-AKI risk and whether dose matters. Prospective
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term statin therapy at the time of exposure to IRCM miti-
gates the risk of CI-AKI in at-risk patients. Finally, the
mechanisms by which statins reduce the risk of CI-AKI in
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